108 related articles for article (PubMed ID: 8917348)
41. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
42. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
43. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.
Smith PC; Keller ET
Prostate; 2001 Jun; 48(1):47-53. PubMed ID: 11391686
[TBL] [Abstract][Full Text] [Related]
44. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
45. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
46. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
Taetle R; Dos Santos B; Akamatsu K; Koishihara Y; Ohsugi Y
Clin Cancer Res; 1996 Feb; 2(2):253-9. PubMed ID: 9816167
[TBL] [Abstract][Full Text] [Related]
47. Optimizing therapeutic strategies to inhibit circulating soluble target molecules with monoclonal antibodies: example of the soluble IL-6 receptors.
Brochier J; Liautard J; Jacquet C; Gaillard JP; Klein B
Eur J Immunol; 2001 Jan; 31(1):259-64. PubMed ID: 11265642
[TBL] [Abstract][Full Text] [Related]
48. Mouse-human chimeric antibody against the multidrug transporter P-glycoprotein.
Hamada H; Miura K; Ariyoshi K; Heike Y; Sato S; Kameyama K; Kurosawa Y; Tsuruo T
Cancer Res; 1990 Jun; 50(11):3167-71. PubMed ID: 1970754
[TBL] [Abstract][Full Text] [Related]
49. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
50. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders.
Junghans RP; Waldmann TA; Landolfi NF; Avdalovic NM; Schneider WP; Queen C
Cancer Res; 1990 Mar; 50(5):1495-502. PubMed ID: 2406013
[TBL] [Abstract][Full Text] [Related]
51. Antitumor xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D.
Johnson DA; Laguzza BC
Cancer Res; 1987 Jun; 47(12):3118-22. PubMed ID: 3495327
[TBL] [Abstract][Full Text] [Related]
52. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma.
Kamath AV; Lu D; Gupta P; Jin D; Xin Y; Brady A; Stephan JP; Li H; Tien J; Qing J; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1071-8. PubMed ID: 22203368
[TBL] [Abstract][Full Text] [Related]
53. Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.
Villunger A; Egle A; Kos M; Hittmair A; Maly K; Greil R
Int J Cancer; 1996 Feb; 65(4):498-505. PubMed ID: 8621234
[TBL] [Abstract][Full Text] [Related]
54. [Advances in the pathogenesis, biology, and management of multiple myeloma].
Kosaka M
Rinsho Byori; 1996 Aug; 44(8):743-9. PubMed ID: 8816060
[TBL] [Abstract][Full Text] [Related]
55. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor.
Yoshio-Hoshino N; Adachi Y; Aoki C; Pereboev A; Curiel DT; Nishimoto N
Cancer Res; 2007 Feb; 67(3):871-5. PubMed ID: 17283116
[TBL] [Abstract][Full Text] [Related]
56. Humanized anti-interleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro.
Hirata T; Shimazaki C; Sumikuma T; Ashihara E; Goto H; Inaba T; Koishihara Y; Nakagawa M
Leuk Res; 2003 Apr; 27(4):343-9. PubMed ID: 12531226
[TBL] [Abstract][Full Text] [Related]
57. Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro.
Goto H; Shimazaki C; Tatsumi T; Yamagata N; Hirata T; Ashihara E; Oku N; Inaba T; Fujita N; Koishihara Y
Jpn J Cancer Res; 1994 Sep; 85(9):958-65. PubMed ID: 7961126
[TBL] [Abstract][Full Text] [Related]
58. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells.
Kim D; Wang J; Willingham SB; Martin R; Wernig G; Weissman IL
Leukemia; 2012 Dec; 26(12):2538-45. PubMed ID: 22648449
[TBL] [Abstract][Full Text] [Related]
59. Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma.
Taetle R; Dos Santos B; Ohsugi Y; Koishihara Y; Yamada Y; Messner H; Dalton W
J Natl Cancer Inst; 1994 Mar; 86(6):450-5. PubMed ID: 8120920
[TBL] [Abstract][Full Text] [Related]
60. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.
van Zaanen HC; Koopmans RP; Aarden LA; Rensink HJ; Stouthard JM; Warnaar SO; Lokhorst HM; van Oers MH
J Clin Invest; 1996 Sep; 98(6):1441-8. PubMed ID: 8823310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
